VIVANI MED.INC. NEW O.N. (F:U5P) — Market Cap & Net Worth
Market Cap & Net Worth: VIVANI MED.INC. NEW O.N. (U5P)
VIVANI MED.INC. NEW O.N. (F:U5P) has a market capitalization of $87.85 Million (€75.14 Million) as of May 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #19673 globally and #1805 in its home market, demonstrating a -7.21% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying VIVANI MED.INC. NEW O.N.'s stock price €1.03 by its total outstanding shares 72952235 (72.95 Million).
VIVANI MED.INC. NEW O.N. Market Cap History: 2015 to 2026
VIVANI MED.INC. NEW O.N.'s market capitalization history from 2015 to 2026. Data shows change from $481.71 Million to $87.85 Million (-16.36% CAGR).
VIVANI MED.INC. NEW O.N. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how VIVANI MED.INC. NEW O.N.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of U5P by Market Capitalization
Companies near VIVANI MED.INC. NEW O.N. in the global market cap rankings as of May 3, 2026.
Key companies related to VIVANI MED.INC. NEW O.N. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
VIVANI MED.INC. NEW O.N. Historical Marketcap From 2015 to 2026
Between 2015 and today, VIVANI MED.INC. NEW O.N.'s market cap moved from $481.71 Million to $ 87.85 Million, with a yearly change of -16.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €87.85 Million | +6.19% |
| 2025 | €82.73 Million | -6.73% |
| 2024 | €88.70 Million | +13.04% |
| 2023 | €78.47 Million | +14.29% |
| 2022 | €68.66 Million | -45.24% |
| 2021 | €125.37 Million | -22.63% |
| 2020 | €162.05 Million | +192.31% |
| 2019 | €55.44 Million | -9.72% |
| 2018 | €61.41 Million | -57.87% |
| 2017 | €145.76 Million | -9.82% |
| 2016 | €161.62 Million | -66.45% |
| 2015 | €481.71 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of VIVANI MED.INC. NEW O.N. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $87.85 Million USD |
| MoneyControl | $87.85 Million USD |
| MarketWatch | $87.85 Million USD |
| marketcap.company | $87.85 Million USD |
| Reuters | $87.85 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About VIVANI MED.INC. NEW O.N.
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease and medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatid… Read more